Arbutus Biopharma Corp business relationships
Companies named in Arbutus Biopharma Corp’s 10-K filed 2026-03-23, and public companies whose annual reports name Arbutus Biopharma Corp. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 0 / 100
Named in Arbutus Biopharma Corp’s annual report 3
“• We depend on our license agreement with Alnylam Pharmaceuticals, Inc. for the commercialization of ONPATTRO™ (Patisiran).” SEC filing
“The Company is also receiving a second royalty interest ranging from 0.75 % to 1.125 % on global net sales of ONPATTRO, with 0.75 % applying to sales greater than $ 500 million, originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (Acuitas).” SEC filing
“Third Amendment to Cross License Agreement, dated December 9, 2021, by and between the Company and Genevant Sciences GmbH (incorporated herein by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on December 10, 2021).” SEC filing
Companies whose annual reports name Arbutus Biopharma Corp 3
“Cross-License Agreement with Arbutus Biopharma Corporation” SEC filing
“The Arbutus Biopharma Agreement was within the scope of the collaborative arrangements guidance as both parties were active participants and were exposed to significant risks and rewards dependent on the success of the collaborative activity.” SEC filing
“In partnership with Arbutus Biopharma, we presented end-of-study data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in CHB evaluating the combination of imdusiran ("IDR"), Arbutus' RNAi therapeutic, followed by VTP-300, with or without LDN.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.